TrademarkDir
GALXC PLUS
DEAD

Serial Number

90474748

Owner

Dicerna Pharmaceuticals, Inc.

Attorney

Bridget H. Labutta

Filing Date

Jan 19, 2021

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

GALXC PLUS Trademark

Serial Number: 90474748

GALXC PLUS is a trademark filed by Dicerna Pharmaceuticals, Inc. on January 19, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Dicerna Pharmaceuticals, Inc. (33 trademarks)

Lexington, MA 02421

Entity Type: 03

Trademark Details

Filing Date

January 19, 2021

Registration Date

Not Registered

Published for Opposition

January 16, 2024

Goods & Services

Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections

Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNA interference (RNAi) therapy; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 10, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 10, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 12, 2024 EXRA
SOU EXTENSION 1 GRANTED
Sep 12, 2024 EX1G
SOU EXTENSION 1 FILED
Sep 12, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 12, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 12, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 16, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 16, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 27, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 13, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 10, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 10, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 10, 2023 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Aug 10, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Aug 10, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 11, 2023 GNRN
NON-FINAL ACTION E-MAILED
May 11, 2023 GNRT
NON-FINAL ACTION WRITTEN
May 11, 2023 CNRT
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 6, 2023 RCCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 7, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 7, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 7, 2023 REAP
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sep 7, 2022 RCSC
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 25, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 25, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 25, 2022 REAP
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 7, 2022 RCSC
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 2, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 2, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 2, 2022 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 13, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 13, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 13, 2022 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 5, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 5, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 5, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 5, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 5, 2022 COAR
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 31, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 31, 2021 GNSL
SUSPENSION LETTER WRITTEN
Aug 31, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 12, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 12, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 12, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 27, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jul 27, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jul 27, 2021 CNRT
ASSIGNED TO EXAMINER
Jul 20, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 20, 2021 NWOS
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 25, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 25, 2021 TCCA
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 25, 2021 COAR
NEW APPLICATION ENTERED
Jan 22, 2021 NWAP

Related Trademarks

More from this Owner

ESTRELLA

ESTRELLA

ESTRELLA

ESTRELLA

BOREALIS logo

BOREALIS

BOREALIS

BOREALIS

ATTAIN

ATTAIN

GALXC logo

GALXC